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A b s t r a c t
Introduction: Nonalcoholic fatty liver disease (NAFLD) is one of the most 
common causes of abnormal liver enzymes in adult patients consulted by 
hepatologists. Due to the high prevalence of this disease, most often associ-
ated with obesity, it is necessary to assess the risk of NAFLD, monitoring the 
progression of the disease and the effectiveness of treatment.
Material and methods: We evaluated the intensity of steatosis, inflamma-
tory activity and fibrosis in 36 patients with NAFLD (fatty liver in abdominal 
ultrasound examination), using non-invasive tests: SteatoTest, ActiTest and 
FibroTest. We compared the prevalence of metabolic disorders and hyper-
tension between women and men.
Results: There were no significant differences in analysed parameters of 
metabolic disorders between women and men. In both studied groups, the 
intensity of steatosis and inflammatory changes was similar. However, in 
the male group, the intensity of liver fibrosis was higher.
Conclusions: The tests helped to detect advanced liver fibrosis in patients 
who were diagnosed with liver steatosis in ultrasound examination. Non-in-
vasive diagnostics of liver injury may be useful in screening to select groups 
of patients requiring liver biopsy, as well as in monitoring the course of the 
disease and assessment of the treatment effectiveness. Early detection of 
liver disease may improve the prognosis of these patients.
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Introduction
Non-alcoholic fatty liver disease (NAFLD) is the most common chron-
ic liver disease all over the world. It covers the spectrum of disorders 
such as non-alcoholic fatty liver (NAFL) and non-alcoholic steatohepatitis 
(NASH) without or with fibrosis, liver cirrhosis (LC), and hepatocellular 
carcinoma (HCC) [1]. The NAFL is the result of an imbalance between 
the formation of triglycerides (TG) and their utilization [2]. It is associ-
ated with excessive accumulation of TG in hepatocytes due to excessive 
inflow of free fatty acids and de novo lipogenesis and impaired TG ex-
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port from the liver in the form of very low densi-
ty lipoprotein (VLDL), which increases the pool of 
lipids accumulated in the liver [2, 3]. Enlarged ad-
ipocytes in adipose tissue decrease the ability to 
store fat and are resistant to the anti-lipolytic ef-
fect of insulin [4]. Insulin resistance is considered 
to be the key pathophysiological factor in NAFLD. 
In addition, increased lipid peroxidation, reactive 
oxygen species (ROS) and oxidative stress stim-
ulate the pro-inflammatory response in the liver 
[5]. This leads to the development of NASH with 
LC and HCC. It has been demonstrated that HCC 
develops five times more often in liver without cir-
rhosis in patients with NAFLD than in other aetiol-
ogies [6]. The risk factors for NAFLD are metabolic 
syndrome, male sex, age over 50 years, type 2 dia-
betes (T2DM), hypertension and increased alanine 
aminotransferase (ALT) activity [1].
The NAFLD occurs in 95% of obese people [7] 
and in 7% of people with normal body weight [8]. 
It is considered to be a  liver manifestation of the 
metabolic syndrome, which is a combination of fac-
tors that increase the risk of atherosclerosis, type 2 
diabetes, and cardiovascular complications [9, 10].
In the POLSenior population study, NAFL was 
diagnosed in 37.2% of the population (> 65 years 
old), and 14.8% of people had advanced liver 
fibro sis, which increased with age [11].
Liver biopsy is the only test that enables un-
questionable differentiation between NAFL and 
NASH [12]. However, it is recommended in patients 
with NAFLD with an increased risk of NASH and 
advanced fibrosis, and in patients with suspicion 
of NAFLD, in whom without biopsy another aeti-
ology of the liver steatosis or coexistence of other 
chronic liver diseases cannot be ruled out [1, 13].
Taking into consideration the aging of societ-
ies and the increasing prevalence of obesity and 
diabetes, a  further increase in the prevalence of 
NAFLD over the next decades should be assumed. 
Therefore, basic imaging examinations such as 
ultrasound (USG), which is, according to current 
recommendations, the basic imaging study in the 
diagnosis of NAFLD and non-invasive diagnostic 
tests for assessing the severity of fatty liver and 
fibrosis in the liver are used in screening and pop-
ulation studies [1]. Non-invasive diagnostic tests 
may be useful in the early detection of liver dam-
age, prognosis of the course of the disease and 
assessment of the effectiveness of treatment. 
FibroMax (BioPredictive, Paris, France) is one 
such non-invasive test. It is considered a universal 
biomarker for chronic liver disease, and includes 
a combination of FibroTest for quantitative fibro-
sis assessment, SteatoTest for quantitative ste-
atosis and ActiTest for the quantitative evaluation 
of inflammatory activity. These tests may be use-
ful in assessing the risk of fibrosis and cirrhosis 
in people with chronic liver disease. FibroMax 
was validated in a  FLIP (Fatty liver: Inhibition of 
Progression) prospective cohort study in patients 
with histologically confirmed NAFLD [14]. The re-
sults of the studies showed that FibroTest, Acti-
Test and SteatoTest have very high compliance 
with histological results in NAFLD; hence they can 
be an alternative to liver biopsy [14, 15].
SteatoTest, ActiTest and FibroTest have been 
patented as in vitro diagnostic tests for the diag-
nosis of fibrosis stages in relation to the METAVIR 
scale [14].
The aim of this study was to assess the intensi-
ty of steatosis, inflammatory activity and fibrosis 
using FibroMax in patients with hepatic steatosis 
in USG and to compare the results between the 
group of women and men.
Material and methods
We examined 36 patients who came for con-
sultation due to fatty liver in the USG with normal 
or elevated liver enzymes activity: 19 men (21–51 
years old, body mass index (BMI): 20.8–34.1 kg/
m2) and 17 women (27–64 years old, BMI: 20.3–
33.9 kg/m2) – Table I. All participants expressed 
their written consent to participate in the study. 
A  questionnaire regarding alcohol consumption, 
coexistence of dyslipidaemia, diabetes mellitus, 
hypertension and medication was carried out in 
all participants. People with a  history of alcohol 
consumption > 20 g/day, viral and autoimmune 
liver disease were excluded from our study. The 
Table I. Demographic data and concomitant diseases in the group of women and men
Parameter Total Women Men
Group size 36 17 19
Mean age (min.–max.) [years] 44.1 (21–64) 49.8 (27–64) 39 (21–51)
BMI (min.–max.) [kg/m2] 27.5 (20.3–38.1) 25.5 (19.8–38.1) 29.7 (20.8–34.1)
Duration of disease (min.–max.) [years] 6.3 (1–31) 8 (1–31) 4.8 (1–15)
Fasting hyperglycaemia/T2DM 9 4 5
Hypertension 8 4 4
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height and weight of all participants were evaluat-
ed and blood samples were collected to determine 
activity of liver enzymes and FibroMax, including: 
FibroTest, ActiTest and SteatoTest, producer: Bio-
Predictive, Paris, France [16].
The results of these tests are calculated as algo-
rithms of clinical and biochemical parameters in the 
range of 0–1. FibroTest is calculated based on the 
concentration of α2-macroglobulin, haptoglobin, 
apolipoprotein A1, total bilirubin and GGT, adjusted 
for age and sex. ActiTest additionally includes ALT, 
and ST: additionally total cholesterol, fasting glu-
cose, triglycerides, height and weight [17].
Statistical analysis
The results of the study were statistically anal-
ysed using free software for statistical computing 
and graphics – the R program.
Results
In the studied group M vs. W hypercholestero-
laemia was found in 21% vs. 23%, hypertriglyce-
ridaemia in 32% vs. 28%, fasting hyperglycaemia 
47% vs. 41%, hypertension in 21% vs. 23% of pa-
tients. In SteatoTest: no or minimal steatosis was 
observed in 31% of men vs. 35% of women, signifi-
cant or severe in 69% of men vs. 65% of women. In 
ActiTest: men vs. women, no or mild inflammatory 
activity (A0–A1) was found in 57% vs. 59%, moder-
ate and severe (A2–A3) in 43% vs. 41% of subjects. 
In FibroTest: men vs. women no or moderate fibro-
sis (F0–F2) was found in 79% vs. 88% advanced 
(F3) in 21% vs. 12% of patients (Table II).
The results of our study did not show statisti-
cally significant differences in the analysed met-
abolic disorders between groups of women and 
men. In both groups, the intensity of steatosis and 
inflammatory activity was similar. However, in the 
male group, a greater degree of fibrosis was ob-
served (Figures 1–3). 
Table II. Results of laboratory tests in the group of women and men
Parameter
(laboratory standards)
Mean total
(min.–max.)
Mean female
(min.–max.)
Mean male
(min.–max.)
P-value 
F/M
Bilirubin (0.0–21.0 mmol/l) 15.2 (6–41) 12.8 (6–23) 17.4 (7–41) 0.1
GGT (F: 5–36; M: 8–61 U/l) 119.1 (23–477) 95 (23–457) 140.6 (24–477) 0.057
ALT (F: 5–33; M: 5–41 U/l) 60 (15–220) 62.6 (15–220) 57.6 (14–140) 0.72
AST (F: 5–32; M: 5–40 IU/l) 50.7 (19–171) 53.5 (19–171) 48.2 (20–161) 0.69
Fasting glucose (3.3–5.6 mmol/l) 5.8 (3.7–10.8) 6.2 (4.4–10.8) 5.4 (3.7–7.8) 0.23
Total cholesterol (3.2–5.2 mmol/l) 5.3 (3.15–8.03) 5.0 (3.1–7.8) 5.5 (4.1–8.0) 0.3
Triglycerides (< 2.26 mmol/l) 1.7 (0.57–3.11) 1.6 (0.6–3.1) 1.9 (0.7–2.8) 0.29
FibroTest 0.31 (0.03–0.78) 0.28 (0.03–0.78) 0.33 (0.05–0.78) 0.44
ActiTest 0.355 (0.04–0.94) 0.33 (0.04–0.93) 0.37 (0.09–0.94) 0.65
SteatoTest 0.55 (0.11–0.88) 0.54 (0.11–0.88) 0.56 (0.2–0.83) 0.73
Figure 2. Degree of necroinflammatory activity in 
the group of women and men. Interpretation of 
the ActiTest: assignment of results to the degree 
of fibrosis in histological classification METAVIR 
1.00 (A3), 0.61–0.62 (A2–A3), 0.53–0.60 (A1–A2), 
0.53–0.60 (A2), 0.37–0.52 (A1–A2), 0.30–0.36 (A1), 
0.18–0.29 (A0–A1), 0.00–0.17 (A0)
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Figure 1. Degree of fatty liver in the group of 
women and men. Interpretation of the SteatoTest:  
S0 – no steatosis, S1 – minimal (1–5%), significant 
S2 (6–32%), heavy S3 (> 32%)
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Discussion
In our study, all examined patients were diag-
nosed with fatty liver in USG, and about 30% with 
metabolic syndrome. Elevated ALT activity was 
found in 71% of women and 69% of men, abnormal 
GGT in 65% of women and 74% of men. According 
to the currently valid criteria, it indicates that the 
majority of patients were NASH patients and not 
simple NAFL patients. Normal or periodically normal 
activity of liver enzymes and the incidence of their 
elevation probably do not reflect the true prevalence 
of NAFLD [8]. In the population of the United States, 
an increase of transaminases was noted in 7.9% of 
subjects, more often in men than in women (9.35 
vs. 6.6%); however, after exclusion of excessive al-
cohol consumption, hepatitis B and C and haemo-
chromatosis, the cause of abnormalities was not 
identified in up to 69% of those examined. However 
the increase of transaminases was associted in both 
women and men groups withwith higher BMI, higher 
triglycerides, fasting glucose, type 2 diabetes and hy-
pertension, which may indicate NAFLD [18], whereas 
elevated GGT activity is considered an NAFLD marker 
in patients with metabolic syndrome [19].
In our study BMI ≥ 25 kg/m2 was observed in 
82% of women and 89% of men. However, NAFLD 
was also observed in patients with normal body 
weight and it was independently associated with 
younger age, female sex, less likelihood of insulin 
resistance and hypercholesterolaemia [8]. There-
fore, prophylactic ultrasound should be performed 
in both normal body weight and overweight or 
obese people with the aim of early detection of 
NAFL. The results of the meta-analysis of Hernaez 
et al. showed that ultrasound examination is an 
accurate and sensitive tool for the detection of 
moderate and severe liver steatosis with sensitivi-
ty and specificity of 84.8% and 93.6%, respectively 
[20]. In the NHANTES III population study conduct-
ed in the USA on a group of 20 050 participants, on 
the basis of clinical presentation, laboratory tests 
and ultrasound examination, NAFLD was diag-
nosed in 2492 people (18.77%), of whom 11.78% 
fulfilled NASH criteria [8]. Patients who have been 
diagnosed with hepatic steatosis without elevated 
liver enzymes should be evaluated for the pres-
ence of metabolic syndrome risk factors and other 
factors that may lead to steatosis, first of all alco-
holic steatosis, whereas subjects with fatty liver in 
imaging examination and abnormal liver enzymes 
should be evaluated for NAFLD [21]. Non-invasive 
diagnostic tests can be used as first-line tests to 
rule out severe liver disease [1].
In our study, no or minimal liver steatosis was 
found in 1/3 of patients, and in 2/3 advanced 
or severe liver steatosis in women and men. In-
creased inflammatory activity was found in more 
than 40% of subjects, whereas advanced fibrosis 
was found almost twice as often in men (21%) 
than in women (12%). 
A  meta-analysis of 30 studies in which 6378 
patients with FT and liver biopsies (3501 HCV, 
1457 HBV, 267 NAFLD, 4229 ALD, 724 mixed aeti-
ology) showed that the diagnostic value of FT, by 
analogy to the liver biopsy, was similar in the four 
most common aetiologies, and as in the case of 
a biopsy, it was higher in advanced fibrosis F2–F4 
than F0–F1 [22]. Therefore, according to Poynard 
et al., a liver biopsy recommended for millions of 
people at risk of fibrosis due to insufficient bene-
fit/risk ratio (risk of death 0.3%) should be a sec-
ond choice procedure for diagnostically difficult 
liver diseases [22].
The diagnostic usefulness of FibroTest, ActiTest 
and SteatoTest tests in people with severe obesity 
was also confirmed, which may also reduce the 
need for biopsy in this group of patients [14, 23].
The results of our research indicating a  high 
percentage of patients with hepatic fibrosis re-
ferred to a  hepatological outpatient clinic with 
fatty liver in USG and normal or abnormal liver 
enzymes confirm the importance of non-invasive 
diagnostics in screening tests, as it is impossible 
to perform liver biopsies in all such patients. Early 
detection of liver disease and introduced dietetic 
treatment, lifestyle modification, increased phys-
ical activity and weight loss, and intensification 
of treatment of metabolic syndrome, may signifi-
cantly improve the prognosis of these people not 
only in preventing fibrosis, cirrhosis and HCC, but 
also in preventing cardiovascular complications.
In conclusion, the results of our study confirm 
that non-invasive diagnostics of liver injury in 
NAFLD may be useful as a  screening method in 
people who have had fatty liver disease identified 
in an ultrasound examination. It can also be help-
Figure 3. Degree of liver fibrosis in the group of 
women and men. Interpretation of the FibroTest: 
assignment of results to the degree of fibrosis in 
histological classification METAVIR: 0.75–1.00 (F4), 
0.73–0.74 (F3–F4), 0.59–0.72 (F3), 0.49–0.58 (F2), 
0.32–0.48 (F1–F2), 0.28–0.31 (F1), 0.22–0.27 (F0–
F1), 0.22–0.27 (F0–F1), 0.00–0.21 (F0)
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ful in monitoring the course of the disease and 
assessing the effectiveness of treatment.
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